484 related articles for article (PubMed ID: 16494499)
21. Role of hypothalamic neuropeptide Y in feeding and obesity.
Gehlert DR
Neuropeptides; 1999 Oct; 33(5):329-38. PubMed ID: 10657510
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the cloned atlantic cod neuropeptide Y-Yb receptor: peptide-binding requirements distinct from known mammalian Y receptors.
Sharma P; Arvidsson AK; Wraith A; Beck-Sickinger AG; Jönsson-Rylander AC; Larhammar D
Gen Comp Endocrinol; 1999 Sep; 115(3):422-8. PubMed ID: 10480994
[TBL] [Abstract][Full Text] [Related]
23. Novel modified and radiolabelled neuropeptide Y analogues to study Y-receptor subtypes.
Koglin N; Beck-Sickinger AG
Neuropeptides; 2004 Aug; 38(4):153-61. PubMed ID: 15337368
[TBL] [Abstract][Full Text] [Related]
24. Characterization of G protein and phospholipase C-coupled agonist binding to the Y1 neuropeptide Y receptor in rat brain: sensitivity to G protein activators and inhibitors and to inhibitors of phospholipase C.
Parker SL; Parker MS; Sweatman T; Crowley WR
J Pharmacol Exp Ther; 1998 Jul; 286(1):382-91. PubMed ID: 9655883
[TBL] [Abstract][Full Text] [Related]
25. Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage functions in vitro: counter regulation through Y1 and Y2/5 receptors.
Dimitrijević M; Stanojević S; Vujić V; Beck-Sickinger A; von Hörsten S
Regul Pept; 2005 Jan; 124(1-3):163-72. PubMed ID: 15544855
[TBL] [Abstract][Full Text] [Related]
26. Neuropeptide Y: multiple receptors and multiple roles in cardiovascular diseases.
Pons J; Lee EW; Li L; Kitlinska J
Curr Opin Investig Drugs; 2004 Sep; 5(9):957-62. PubMed ID: 15503651
[TBL] [Abstract][Full Text] [Related]
27. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
Gehlert DR; Schober DA; Morin M; Berglund MM
Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
[TBL] [Abstract][Full Text] [Related]
28. NPY and Y receptors: lessons from transgenic and knockout models.
Lin S; Boey D; Herzog H
Neuropeptides; 2004 Aug; 38(4):189-200. PubMed ID: 15337371
[TBL] [Abstract][Full Text] [Related]
29. GPC receptors and not ligands decide the binding mode in neuropeptide Y multireceptor/multiligand system.
Lindner D; van Dieck J; Merten N; Mörl K; Günther R; Hofmann HJ; Beck-Sickinger AG
Biochemistry; 2008 Jun; 47(22):5905-14. PubMed ID: 18457425
[TBL] [Abstract][Full Text] [Related]
30. Molecular characterization of the human neuropeptide Y Y2-receptor.
Ingenhoven N; Eckard CP; Gehlert DR; Beck-Sickinger AG
Biochemistry; 1999 May; 38(21):6897-902. PubMed ID: 10346911
[TBL] [Abstract][Full Text] [Related]
31. Expression of neuropeptide Y receptors mRNA and protein in human brain vessels and cerebromicrovascular cells in culture.
Abounader R; Elhusseiny A; Cohen Z; Olivier A; Stanimirovic D; Quirion R; Hamel E
J Cereb Blood Flow Metab; 1999 Feb; 19(2):155-63. PubMed ID: 10027771
[TBL] [Abstract][Full Text] [Related]
32. Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5).
Dumont Y; Cadieux A; Doods H; Fournier A; Quirion R
Can J Physiol Pharmacol; 2000 Feb; 78(2):116-25. PubMed ID: 10737674
[TBL] [Abstract][Full Text] [Related]
33. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system.
Pons J; Kitlinska J; Ji H; Lee EW; Zukowska Z
Can J Physiol Pharmacol; 2003 Feb; 81(2):177-85. PubMed ID: 12710532
[TBL] [Abstract][Full Text] [Related]
34. Introduction to the reviews on neuropeptide Y.
Gehlert DR
Neuropeptides; 2004 Aug; 38(4):135-40. PubMed ID: 15337366
[TBL] [Abstract][Full Text] [Related]
35. Role of the C terminus in neuropeptide Y Y1 receptor desensitization and internalization.
Holliday ND; Lam CW; Tough IR; Cox HM
Mol Pharmacol; 2005 Mar; 67(3):655-64. PubMed ID: 15576634
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and evaluation of new hydrazide derivatives as neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
Juanenea L; Galiano S; Erviti O; Moreno A; Pérez S; Aldana I; Monge A
Bioorg Med Chem; 2004 Sep; 12(17):4717-23. PubMed ID: 15358298
[TBL] [Abstract][Full Text] [Related]
37. Structural basis of ligand binding modes at the neuropeptide Y Y
Yang Z; Han S; Keller M; Kaiser A; Bender BJ; Bosse M; Burkert K; Kögler LM; Wifling D; Bernhardt G; Plank N; Littmann T; Schmidt P; Yi C; Li B; Ye S; Zhang R; Xu B; Larhammar D; Stevens RC; Huster D; Meiler J; Zhao Q; Beck-Sickinger AG; Buschauer A; Wu B
Nature; 2018 Apr; 556(7702):520-524. PubMed ID: 29670288
[TBL] [Abstract][Full Text] [Related]
38. Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms.
Gao J; Ghibaudi L; Hwa JJ
Am J Physiol Endocrinol Metab; 2004 Oct; 287(4):E706-11. PubMed ID: 15187000
[TBL] [Abstract][Full Text] [Related]
39. Neuropeptide Y induces gonadotropin-releasing hormone gene expression directly and through conditioned medium from mHypoE-38 NPY neurons.
Dhillon SS; Gingerich S; Belsham DD
Regul Pept; 2009 Aug; 156(1-3):96-103. PubMed ID: 19371763
[TBL] [Abstract][Full Text] [Related]
40. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors.
Henry M; Ghibaudi L; Gao J; Hwa JJ
Obes Res; 2005 Jan; 13(1):36-47. PubMed ID: 15761161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
